Skip to main content

Table 1 Patients groups characteristics (N = 294)

From: Retrospective analysis of the impact of anthracycline dose reduction and chemotherapy delays on the outcomes of early breast cancer molecular subtypes

Characteristics n 5 year survival (%) p overall (log rank test)
Treatment period
 2004 152 80.3 p = .42
 2005 97 79.4
 2006 21 90.0
 2007 19 68.4
Tumor stage
 I 67 83.2 P < .001
pairwise comparisons
1–3, **, 2–3 **
 II 201 81.0
 III 26 50.0
Lymph node involvement
 Not involved 179 82.0 p = .51
 Involved 115 76.8
ER and HER2 receptor status
 ER-HER2- 85 66.5 p = .002
pairwise comparisons
1–3 *, 3–4 *
1–4 **
 ER-HER2+ 17 87.5
 ER + HER2- 143 79.8
 ER + HER2+ 49 93.9
Menopausal status
 Pre/perimenopausal 94 85.3 p < .05
 Postmenopausal 200 75.5
Delayed number of cycles
  ≤ 2 delayed cycles 187 86.3 p < .001
  > 2 delayed cycles 107 65.4
Delayed number of days at any cycle
  ≤ 7 days 217 81.1 p = .093
 ˃7 days 77 71.8
Dose reduction
  ≤ 15% 225 89.7 p < .001
 ˃ 15% 69 65.4
Anthracycline delay/reduction groups
 No anthracyclines reduction or delays 179 86.4 p < .001
pairwise comparisons
1–2, 1–4 **
2–3, 3–4 *
1–3, 2–4 ns
 Anthracycline reduction only 38 57.6
 Anthracycline delays only 46 79.5
 Both anthracycline reduction and delays 31 60.2
  1. pairwise comparisons *p < .05, ** p < .001, ns – not signifficant